Author

DJ Serie

Institutions: Nanostring Technologies (United States), NRG Oncology

Observed institutions: Broad Institute, University of North Carolina at Chapel Hill, Sage Bionetworks, Mayo Clinic, University of Helsinki, The University of Texas MD Anderson Cancer Center, Baylor College of Medicine, Washington University in St. Louis, Helsinki University Hospital, University of Chicago, Massachusetts General Hospital, Nanostring Technologies (United States), Mayo Clinic in Florida, NRG Oncology, Mayo Clinic Comprehensive Cancer Center (Florida), UNC Lineberger Comprehensive Cancer Center, Canadian Cancer Trials Group

OpenAlex ID: A5028800294

Abstract PD3-02: Incidence of late relapse in HER2-positive (HER2+) breast cancer patients receiving adjuvant trastuzumab: Combined analysis of NCCTG (Alliance) N9831 and NSABP (NRG) B31

2019 · S Chumsri, Z Li, et al. · Cancer Research · 6

Abstract PD3-18: The NSABP/NRG 8-gene signature accurately predicts degree of benefit from trastuzumab in Alliance/NCCTG N9831: Validation of the 8-gene signature in an independent clinical trial

2018 · KL Pogue-Geile, N Song, et al. · Cancer Research · 4

Abstract S4-02: A comprehensive analysis of fusion transcripts in breast cancer reveals associations between number of fusion transcripts, copy number events, gene expression profiles, and potentially clinical outcome

2016 · EA Thompson, YW Asmann, et al. · Cancer Research · 3

Abstract PD5-06: Prognostic value of molecular tumor infiltrating lymphocyte (mTIL) signatures in HER2-positive breast cancer patients in N9831 and FinHer/FinXX trials

2017 · S Chumsri, DJ Serie, et al. · Cancer Research

Abstract P2-09-03: Mammographic Density Response to Aromatase Inhibitor Therapy

2010 · CM Vachon, KR Brandt, et al. · Cancer Research

Works count: 5

Citation count: 13

H-index: 3

I10-index: